Heart rhythm showdown: ablation may beat drugs for ventricular tachycardia

NCT ID NCT05524077

Ongoing Disease control Sponsor: Western Sydney Local Health District Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests whether a procedure called catheter ablation works better than anti-arrhythmic drugs for people with structural heart disease who have had a dangerous fast heart rhythm (ventricular tachycardia). About 162 participants will be randomly assigned to either ablation or standard drug therapy. The goal is to see which approach better reduces repeat episodes, life-threatening storms of fast rhythms, and death over about 18 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: catheter ablation (a procedure using a thin tube to destroy heart tissue causing abnormal rhythms)
What this could lead to: If successful, this could show that catheter ablation is a better first-line treatment than drugs for controlling dangerous heart rhythms and reducing hospital visits.
What could go wrong: This is a mid-sized trial (162 people) and results may not apply to all heart disease types. Ablation is invasive and carries risks like bleeding or heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARRHYTHMOGENIC LEFT VENTRICULAR CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arrhythmogenic right ventricular dysplasia 1 Arrhythmogenic Right Ventricular Dysplasia, Familial, 1 cardiomyopathy dilated cardiomyopathy familial cardiomyopathy familial isolated arrhythmogenic ventricular dysplasia, left dominant form heart disorder hypertrophic cardiomyopathy myocardial ischemia sarcoidosis ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARRHYTHMOGENIC LEFT VENTRICULAR CARDIOMYOPATHY ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 1 CARDIOMYOPATHY ISCHEMIC CARDIOMYOPATHY, DILATED CARDIOMYOPATHY, FAMILIAL CARDIOMYOPATHY, HYPERTROPHIC HEART DISEASE STRUCTURAL DISORDER SARCOIDOSIS VENTRICULAR TACHYCARDIA

Contacts and locations

Locations

Gold Coast University Hospital

Southport, Queensland, 4215, Australia
John Hunter Hospital

New Lambton Heights, New South Wales, 2305, Australia
Nepean Hospital

Kingswood, New South Wales, 2747, Australia
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia
Royal North Shore Hospital

Saint Leonards, New South Wales, 2065, Australia
Royal Prince Alfred Hospital

Camperdown, New South Wales, 2050, Australia
The Alfred Hospital

Melbourne, Victoria, 3004, Australia
The Prince Charles Hospital

Chermside, Queensland, 4032, Australia
Westmead Hospital

Westmead, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.